A Phase III Randomized Study of Maintenance Nivolumab Versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC
EA3161 is temporarily closed to accrual to explore possibility to increase accrual goal effective July 22, 2024.
